ReviewCurrent protein & peptide science2012
Immunoproteomics: the key to discovery of new vaccine antigens against bacterial respiratory infections.
Review in Current protein & peptide science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Characterization of a novelmSphere · 2025Article
- Innovative Immunoinformatics Tools for Enhancing MHC (Major Histocompatibility Complex) Class I Epitope Prediction in Immunoproteomics.Protein and peptide letters · 2025Review
- Immune interface interference vaccines: An evolution-informed approach to anti-bacterial vaccine design.Microbial biotechnology · 2024Article
- Advancing vaccine development againstFrontiers in pharmacology · 2024Review
- Development of an immunogen containing CD4Applied microbiology and biotechnology · 2022Article
- Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.Frontiers in immunology · 2022Article
- The role of pathogens in diabetes pathogenesis and the potential of immunoproteomics as a diagnostic and prognostic tool.Frontiers in microbiology · 2022Review
- A novel vaccine adjuvant based on straight polyacrylate potentiates vaccine-induced humoral and cellular immunity in cynomolgus macaques.Human vaccines & immunotherapeutics · 2021Article
- Immunoproteomic analysis of Clostridium botulinum type B secretome for identification of immunogenic proteins against botulism.Biotechnology letters · 2021Article
- Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation.Pharmaceutics · 2021Review
- Exoproteomics for Better UnderstandingToxins · 2020Review
- Mechanistic research holds promise for bacterial vaccines and phage therapies forDrug design, development and therapy · 2019Review
- Identification of Clostridium difficile Immunoreactive Spore Proteins of the Epidemic Strain R20291.Proteomics. Clinical applications · 2018Article
- Virulence factors of Moraxella catarrhalis outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution.Scientific reports · 2018Article
- Immunoproteomic Analysis of Antibody Response of Rabbit Host Against Heat-Killed Francisella tularensis Live Vaccine Strain.Current microbiology · 2017Article
- Prospects for subunit vaccines: Technology advances resulting in efficacious antigens requires matching advances in early clinical trial investment.Human vaccines & immunotherapeutics · 2016Article
- Linocin and OmpW Are Involved in Attachment of the Cystic Fibrosis-Associated Pathogen Burkholderia cepacia Complex to Lung Epithelial Cells and Protect Mice against Infection.Infection and immunity · 2016Article
- Proteomics As a Tool for Studying Bacterial Virulence and Antimicrobial Resistance.Frontiers in microbiology · 2016Review
- Identification of Novel Immunogenic Proteins of Neisseria gonorrhoeae by Phage Display.PloS one · 2016Article
- Outer membrane vesicles as platform vaccine technology.Biotechnology journal · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase in antibiotic resistance and the shortage of new antimicrobials to prevent difficult bacterial infections underlines the importance of prophylactic therapies to prevent infection by bacterial pathogens. Vaccination has reduced the incidence of many serious diseases, including respiratory bacterial infections. However, there are many pathogens for which no vaccine is available and some vaccines are not effective among all age groups or among immunocompromised individuals. Immunoproteomics is a powerful technique which has been used to identify potential vaccine candidates to protect against pathogenic bacteria. The combination of proteomics with the detection of immunoreactive antigens using serum highlights immunogenic proteins that are expressed during infection. This is particularly useful when patient serum is used as the antigens that promote a humoral response during human infection are identified. This review outlines examples of vaccine candidates that have been identified using immunoproteomics and have successfully protected animals against challenge when tested in immunisation studies. Many immunoreactive proteins are common to several unrelated pathogens, however some of these are not always protective in animal immunisation and challenge studies. Furthermore, examples of well-established immunogens, including Bordetella pertussis antigen FHA were not detected in immunoproteomics studies, indicating that this technology may underrepresent the immunoreactive proteins in a pathogen. Although only one step in the pathway towards an efficacious approved vaccine, immunoproteomics is an important technology in the identification of novel vaccine antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.